Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akeso Inc.
Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
China’s CDE Explains Major Issues Around Conditional Approval Scheme
China's conditional approval system, which is an accelerated pathway, is being increasingly used by pharma firms, but some thorny issues remain such as the impact on full approvals, the scheme’s relation to priority reviews and currently available therapies and deadlines for confirmatory studies. Staff from the country's Center for Drug Evaluation discussed various topics around the system in a recent article.
Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology
Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.
Akeso's Xia Looks Beyond Summit Deal To Independent Global Development, Sales
Last December, China's Akeso struck a major agreement worth up to $5bn with Summit Therapeutics, which set a new record in terms of total deal value for a single asset in the Chinese biopharma sector. Akeso founder and CEO Michelle Xia is now planning to pursue a more independent path in taking the firm global.
- Large Molecule
- Other Names / Subsidiaries
- Akesobio Australia Pty Ltd
- Akeso Biopharma, Inc.
- Kangfang Biotechnology
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.